Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR113244 in SLE
NCT02331810Phase 1Withdrawn
- Sponsor
- Sanofi
- Start
- Apr 2016
- Primary completion
- May 2017
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing SAR113244 with Placebo (2 arms). Primary endpoint: Percentage decrease in B cell subsets (expressed as percentages of total B-cells) from baseline. Planned start Apr 2016; status: withdrawn.
02
Drugs
SAR113244
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02331810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02331810.